Stanislav Vatnitsky

Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience

Charged particle therapy is generally regarded as cutting-edge technology in oncology. Many proton therapy centres are active in the USA, Europe, and Asia, but only a few centres use heavy ions, even though these ions are much more effective than x-rays owing to the special radiobiological properties of densely ionising radiation. The National Institute of Radiological Sciences (NIRS) Chiba, Japan, has been treating cancer with high-energy carbon ions since 1994. So far, more than 8000 patients have had this treatment at NIRS, and the centre thus has by far the greatest experience in carbon ion treatment worldwide. A panel of radiation oncologists, radiobiologists, and medical physicists from the USA and Europe recently completed peer review of the carbon ion therapy at NIRS. The review panel had access to the latest developments in treatment planning and beam delivery and to all updated clinical data produced at NIRS. A detailed comparison with the most advanced results obtained with x-rays or protons in Europe and the USA was then possible. In addition to those tumours for which carbon ions are known to produce excellent results, such as bone and soft-tissue sarcoma of the skull base, head and neck, and pelvis, promising data were obtained for other tumours, such as locally recurrent rectal cancer and pancreatic cancer. The most serious impediment to the worldwide spread of heavy ion therapy centres is the high initial capital cost. The 20 years of clinical experience at NIRS can help guide strategic decisions on the design and construction of new heavy ion therapy centres.

Radiochromic film dosimetry for clinical proton beams

Depth doses and lateral profiles for proton beams with energies of 100-250 MeV were measured with a high-sensitivity GafChromic MD-55 film, which requires no post-irradiation development. The exposed MD-55 films were evaluated with the RIT 113 film dosimetry system. Depth doses measured with MD-55 film were compared with those obtained with a plane-parallel ionization chamber. The GafChromic film was found to be less sensitive at the distal edge for both modulated and unmodulated beams compared with an ionization chamber, however, the difference in penetration of the beam at the depth of 80-50% distal fall-off measured with this film and the ionization chamber is within 0.1-0.2 mm for studied beams. The lateral beam profiles measured with MD-55 film were in a good agreement with profiles obtained from Kodak XV-2 radiographic film, scanned with the Wellhofer densitometer. It is concluded that MD-55 film, with some limitations, is a useful detector for dosimetry measurements in a single proton beam and can be employed for verification dosimetry in multiple-beam radiation therapy.

Radiochromic film dosimetry for verification of dose distributions delivered with proton-beam radiosurgery

In this work we studied the feasibility of radiochromic film for dosimetry verification of proton Bragg peak stereotactic radiosurgery with multiple beams. High-sensitivity MD-55 radiochromic film was calibrated for proton beam irradiation and the RIT 113 system was employed for film evaluation. Simulated stereotactic radiosurgery with a special phantom arrangement for film dosimetry was performed, following the same procedure as for a patient undergoing treatment. Five-beam irradiation was developed using a 3D treatment planning system. This plan was then delivered to the phantom in a one-day experiment. Planned and measured composite dose distributions were compared. Spatial accuracy of dose delivery to a region containing a simulated critical structure was evaluated for a single portal. Radiochromic film dosimetry validated the prescribed dose delivery within +/- 5%, one standard deviation, by comparing calculated doses with measured values. The alignment of apertures and boluses, as well as the alignment of the phantom with respect to the isocentre, was confirmed. Spatial accuracy of the method would have been able to detect possible misalignments greater than +/- 2 mm. We have demonstrated how radiochromic film dosimetry can be used to measure complex dose distributions in an irradiated phantom, thus enabling us to verify planned dose delivery of proton Bragg peak stereotactic radiosurgery with multiple beams. We assume that the dosimetric agreement between planned and measured dose distributions for the reported simulations will apply to patient treatments.

Dosimetry techniques for narrow proton beam radiosurgery

Characterization of narrow beams used in proton stereotactic radiosurgery (PSRS) requires special efforts, since the use of finite size detectors can lead to distortion of the measured dose distributions. Central axis depth doses, lateral profiles and field size dependence factors are the most important beam characteristics to be determined prior to dosimetry calculations and beam modelling for PSRS. In this paper we report recommendations for practical dosimetry techniques which were developed from a comparison of beam characteristics determined with a variety of radiation detectors for 126 and 155 MeV narrow proton beams shaped with 2-30 mm circular brass collimators. These detectors included small-volume ionization chambers, a diamond detector, an Hi-p Si diode, TLD cubes, radiographic and radiochromic films. We found that both types of film are suitable for profile measurements in narrow beams. Good agreement between depth dose distributions measured with ionization chambers, diamond and diode detectors was demonstrated in beams with diameters of 20-30 mm. The diode detector can be used in smaller beams, down to 5 mm diameter. For beams with diameters less than 5 mm, reliable depth dose data may be obtained only with radiochromic film. The tested ionization chambers are appropriate for calibration of beams with diameters of 20-30 mm. TLD cubes and diamond detectors are useful to determine relative dose in beams with diameters of 10-20 mm. Field size factors for smaller beams should be obtained with diode and radiochromic film. We conclude that dosimetry characterization of proton beams down to several millimetres in diameter can be performed using the described procedures.

Proton dosimetry intercomparison

BACKGROUND AND PURPOSE Methods for determining absorbed dose in clinical proton beams are based on dosimetry protocols provided by the AAPM and the ECHED. Both groups recommend the use of air-filled ionization chambers calibrated in terms of exposure or air kerma in a 60Co beam when a calorimeter or Faraday cup dosimeter is not available. The set of input data used in the AAPM and the ECHED protocols, especially proton stopping powers and w-value is different. In order to verify inter-institutional uniformity of proton beam calibration, the AAPM and the ECHED recommend periodic dosimetry intercomparisons. In this paper we report the results of an international proton dosimetry intercomparison which was held at Loma Linda University Medical Center. The goal of the intercomparison was two-fold: first, to estimate the consistency of absorbed dose delivered to patients among the participating facilities, and second, to evaluate the differences in absorbed dose determination due to differences in 60Co-based ionization chamber calibration protocols. MATERIALS AND METHODS Thirteen institutions participated in an international proton dosimetry intercomparison. The measurements were performed in a 15-cm square field at a depth of 10 cm in both an unmodulated beam (nominal accelerator energy of 250 MeV) and a 6-cm modulated beam (nominal accelerator energy of 155 MeV), and also in a circular field of diameter 2.6 cm at a depth of 1.14 cm in a beam with 2.4 cm modulation (nominal accelerator energy of 100 MeV). RESULTS The results of the intercomparison have shown that using ionization chambers with 60Co calibration factors traceable to standard laboratories, and institution-specific conversion factors and dose protocols, the absorbed dose specified to the patient would fall within 3% of the mean value. A single measurement using an ionization chamber with a proton chamber factor determined with a Faraday cup calibration differed from the mean by 8%. CONCLUSION The adoption of a single ionization chamber dosimetry protocol and uniform conversion factors will establish agreement on proton absorbed dose to approximately 1.5%, consistent with that which has been observed in high-energy photon and electron dosimetry.

Application of solid state detectors for dosimetry of therapeutic proton beams

A PTW Riga diamond detector and LiF TLDs have been evaluated for use in proton beam dosimetry by comparing results of proton beam calibration with those obtained using thimble ionization chambers. The thimble ionization chambers were calibrated in terms of exposure while the TLDs and diamond detector were calibrated in terms of absorbed dose in a 60Co beam. Absorbed doses to muscle in proton beams for ionization chambers were derived using the TG 20 charged particle protocol. Absorbed doses to muscle for solid state detectors were derived using absorbed dose proton beam quality correction factors. Differences between the derived doses for ionization chambers and solid state detectors were found to be within the uncertainties of measurements: 4.5% for ionization chambers and 5% for solid state detectors.

Proton dosimetry intercomparison based on the ICRU report 59 protocol

BACKGROUND AND PURPOSE A new protocol for calibration of proton beams was established by the ICRU in report 59 on proton dosimetry. In this paper we report the results of an international proton dosimetry intercomparison, which was held at Loma Linda University Medical Center. The goals of the intercomparison were, first, to estimate the level of consistency in absorbed dose delivered to patients if proton beams at various clinics were calibrated with the new ICRU protocol, and second, to evaluate the differences in absorbed dose determination due to differences in 60Co-based ionization chamber calibration factors. MATERIALS AND METHODS Eleven institutions participated in the intercomparison. Measurements were performed in a polystyrene phantom at a depth of 10.27 cm water equivalent thickness in a 6-cm modulated proton beam with an accelerator energy of 155 MeV and an incident energy of approximately 135 MeV. Most participants used ionization chambers calibrated in terms of exposure or air kerma. Four ionization chambers had 60Co-based calibration in terms of absorbed dose-to-water. Two chambers were calibrated in a 60Co beam at the NIST both in terms of air kerma and absorbed dose-to-water to provide a comparison of ionization chambers with different calibrations. RESULTS The intercomparison showed that use of the ICRU report 59 protocol would result in absorbed doses being delivered to patients at their participating institutions to within +/-0.9% (one standard deviation). The maximum difference between doses determined by the participants was found to be 2.9%. Differences between proton doses derived from the measurements with ionization chambers with N(K)-, or N(W) - calibration type depended on chamber type. CONCLUSIONS Using ionization chambers with 60Co calibration factors traceable to standard laboratories and the ICRU report 59 protocol, a distribution of stated proton absorbed dose is achieved with a difference less than 3%. The ICRU protocol should be adopted for clinical proton beam calibration. A comparison of proton doses derived from measurements with different chambers indicates that the difference in results cannot be explained only by differences in 60Co calibration factors.

kQ factors for ionization chamber dosimetry in clinical proton beams.

We discuss a formalism for clinical proton beam dosimetry based on the use of ionization chamber absorbed dose-to-water calibration and beam quality correction factors. A quantity kQ, the beam quality correction factor, is defined which corrects the absorbed dose-to-water calibration factor ND,w in a reference beam of quality Q0 to that in a users beam of quality Q1. This study of proton beam quality correction factors used 60Co (kQ gamma) and proton (kQp) reference beams. The kQ gamma factors were measured using combined water calorimetry and ionometry for PTW and Capintec-Farmer-type ionization chambers, and were computed from standard dosimetry protocols. Agreement between measured and calculated kQ gamma values for both chambers was found within 1.2% in the plateau region for a monoenergetic 250-MeV beam and within 1.8% at the spread-out Bragg peak for a 155-MeV range-modulated beam. Comparison of absorbed doses to water determined in the range-modulated 155-MeV beam was performed with the PTW chamber using three calibration methods: Ngas calibration (AAPM Report 16), ND,w,gamma calibration in a 60Co beam in conjunction with a kQ gamma factor, and ND,w,p calibration in a proton beam in conjunction with a kQp factor. Absorbed doses to water obtained with the three methods agreed within 2% when ionization chamber dosimetry data were analyzed using the proton W-value for air from the AAPM Report 16 and the ICRU 49 proton stopping powers. The use of the proton-calibrated reference ionization chamber, in conjunction with the beam quality correction factor kQp, significantly reduced the systematic uncertainty of the absorbed dose determination.

Dosimetry auditing procedure with alanine dosimeters for light ion beam therapy

BACKGROUND AND PURPOSE In the next few years the number of facilities providing ion beam therapy with scanning beams will increase. An auditing process based on an end-to-end test (including CT imaging, planning and dose delivery) could help new ion therapy centres to validate their entire logistic chain of radiation delivery. An end-to-end procedure was designed and tested in both scanned proton and carbon ion beams, which may also serve as a dosimetric credentialing procedure for clinical trials in the future. The developed procedure is focused only on physical dose delivery and the validation of the biological dose is out of scope of the current work. MATERIALS AND METHODS The audit procedure was based on a homogeneous phantom that mimics the dimension of a head (20 × 20 × 21 cm(3)). The phantom can be loaded either with an ionisation chamber or 20 alanine dosimeters plus 2 radiochromic EBT films. Dose verification aimed at measuring a dose of 10Gy homogeneously delivered to a virtual-target volume of 8 × 8 × 12 cm(3). In order to interpret the readout of the irradiated alanine dosimeters additional Monte Carlo simulations were performed to calculate the energy dependent detector response of the particle fluence in the alanine detector. A pilot run was performed with protons and carbon ions at the Heidelberg Ion Therapy facility (HIT). RESULTS The mean difference of the absolute physical dose measured with the alanine dosimeters compared with the expected dose from the treatment planning system was -2.4 ± 0.9% (1σ) for protons and -2.2 ± 1.1% (1σ) for carbon ions. The measurements performed with the ionisation chamber indicate this slight underdosage with a dose difference of -1.7% for protons and -1.0% for carbon ions. The profiles measured by radiochromic films showed an acceptable homogeneity of about 3%. CONCLUSIONS Alanine dosimeters are suitable detectors for dosimetry audits in ion beam therapy and the presented end-to-end test is feasible. If further studies show similar results, this dosimetric audit could be implemented as a credentialing procedure for clinical proton and carbon beam delivery.

Calorimetric determination of the absorbed dose-to-water beam quality correction factor kQ for high-energy photon beams.

A method has been developed for measuring photon beam quality correction factors kQ using direct transfer with a water calorimeter. kQ values were measured for beam qualities varying between 6 and 23 MV for a Capintec PR-06 and a PTW W30001 cylindrical ionization chamber. Measured values were intercompared with published sets of computed kQ values and agreement was found to be within measurement uncertainty (1%, one standard deviation).